WO2016167605A3 - Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine - Google Patents

Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine Download PDF

Info

Publication number
WO2016167605A3
WO2016167605A3 PCT/KR2016/003957 KR2016003957W WO2016167605A3 WO 2016167605 A3 WO2016167605 A3 WO 2016167605A3 KR 2016003957 W KR2016003957 W KR 2016003957W WO 2016167605 A3 WO2016167605 A3 WO 2016167605A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
smokers
hypertension medicine
present
clinical application
Prior art date
Application number
PCT/KR2016/003957
Other languages
French (fr)
Korean (ko)
Other versions
WO2016167605A2 (en
Inventor
이호영
민혜영
부혜진
장현지
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160045773A external-priority patent/KR101938036B1/en
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Publication of WO2016167605A2 publication Critical patent/WO2016167605A2/en
Publication of WO2016167605A3 publication Critical patent/WO2016167605A3/en
Priority to US15/784,538 priority Critical patent/US11123335B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method for inhibiting lung cancer of smokers and non-smokers by blocking the signaling of growth factors through the use of a hypertension medicine and, more specifically, to a pharmaceutical composition for preventing or treating lung cancer, containing a hypertension medicine as an active ingredient. The present invention suggests a novel use of a hypertension medicine, currently in clinical use, for preventing lung cancer, and can be directly applied to an early-stage lung cancer or lung cancer high-risk group. Especially, the present invention can exclude the worry of safety, involved in the clinical application of new drugs, thereby increasing the possibility of the clinical application, and significantly reduce enormous costs and time consumed from the development to the clinical application of new drugs.
PCT/KR2016/003957 2015-04-16 2016-04-15 Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine WO2016167605A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/784,538 US11123335B2 (en) 2015-04-16 2017-10-16 Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150053921 2015-04-16
KR10-2015-0053921 2015-04-16
KR1020160045773A KR101938036B1 (en) 2015-04-16 2016-04-14 Method for inhibiting lung carcinogenesis of both smokers and non-smokers by using antihypertensive drugs
KR10-2016-0045773 2016-04-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/784,538 Continuation-In-Part US11123335B2 (en) 2015-04-16 2017-10-16 Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug

Publications (2)

Publication Number Publication Date
WO2016167605A2 WO2016167605A2 (en) 2016-10-20
WO2016167605A3 true WO2016167605A3 (en) 2016-12-29

Family

ID=57126215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003957 WO2016167605A2 (en) 2015-04-16 2016-04-15 Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine

Country Status (1)

Country Link
WO (1) WO2016167605A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147089A1 (en) * 2018-01-26 2019-08-01 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating cancer comprising, as active ingredient, calcium channel inhibitor or pharmaceutically acceptable salt thereof
CN111825599A (en) * 2019-04-17 2020-10-27 上海中医药大学附属龙华医院 Medical application of novel Neddylation inhibitor
CN114621959B (en) * 2020-12-08 2023-05-26 中国科学院海洋研究所 Gene for encoding paralichthys olivaceus IGF2 soluble protein, protein recombinant expression method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
WO2012071573A2 (en) * 2010-11-24 2012-05-31 Mount Sinai School Of Medicine Materials and methods for the prevention and treatment of cancer
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
WO2012071573A2 (en) * 2010-11-24 2012-05-31 Mount Sinai School Of Medicine Materials and methods for the prevention and treatment of cancer
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI, J. ET AL.: "Telmisartsn Exerts Anti-tumor Effects by Activating Peroxisome Proliferator-activated Receptor-y in Human Lung Adenocarcinoma A549 Cells", MOLECULES, vol. 19, no. 3, 5 March 2014 (2014-03-05), pages 2862 - 2876, XP055340534 *
SCHULLER, H. M.: "Effects of Tobacco Constituents and Psychological Stress on the Beta-adrenergic Regulation of Non-small Cell Lung Cancer and Pancreatic Cancer: Implications for Intervention", CANCER BIOMARKERS, vol. 13, no. 3, 1 January 2013 (2013-01-01), pages 133 - 144 *
YASUMARU, M. ET AL.: "Inhibition of Angiotensin II Activity Enhanced the Antitumor Effect of Cyclooxygenase-2 Inhibitors via Insulin-like Growth Factor I Receptor Pathway", CANCER RESEARCH, vol. 63, no. 20, 15 October 2003 (2003-10-15), pages 6726 - 6734, XP055340535 *

Also Published As

Publication number Publication date
WO2016167605A2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
PH12019501685A1 (en) Quinazone compound
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2016016593A (en) Novel aminoalkyl benzothiazepine derivative and use thereof.
SG10201900315SA (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2018011788A (en) Substituted indoline derivatives as dengue viral replication inhibitors.
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
PH12016502352A1 (en) Pharmaceutical composition
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
TW201613578A (en) Pharmaceutical combinations
WO2016046260A8 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX2017003561A (en) Compositions and methods for cannabinoid coatings for use in drug delivery.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2016167605A3 (en) Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine
MX2018008153A (en) C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same.
MX2017002544A (en) Isoquinolinone derivatives useful in the treatment of cancer.
EP3610866A4 (en) Pharmaceutical composition for preventing and treating cancer, containing malate-aspartate shuttle inhibitor and anticancer drug as active ingredients
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
IL284132A (en) Pharmaceutical compound, the method of its making and use as medicinal agent
IN2014DN10683A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16780328

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16780328

Country of ref document: EP

Kind code of ref document: A2